The FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.
FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA In Brief: FDA Publishes Material Safety Data to Promote Safer, More Effective Medical Devices
- FDA Issues Draft Guidance on Donor Eligibility and Manufacturing of Cellular Therapies for Animals
- FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations
- Cordis Recalls SUPER TORQUE MB Angiographic Catheter with Radiopaque Marker Bands Due to Potential for Marker Bands to Move or Dislodge